Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,843 across all filing types
Latest filing 2013-08-02 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
关于受让海正药业药品技术的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's acquisition of pharmaceutical technology from another company. It details the transaction, including the parties involved, the amount, and the strategic rationale. There is no indication that this is a full financial report, audit, or regulatory filing. It is not a merger or takeover bid but rather a capital transaction related to technology acquisition. The document is relatively short and focused on a specific transaction update. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2013-08-02 Chinese
关于完成注册资本工商变更登记的公告
Share Issue/Capital Change Classification · 95% confidence The document is a short announcement regarding the completion of a change in registered capital and related business registration procedures. It mentions the approval of a capital increase plan by the shareholders and the official update of the company's registered capital with the local administration. The document is brief (471 characters) and serves as a formal notice of a capital change rather than a detailed financial report or analysis. It does not contain financial statements or detailed financial data. Therefore, it fits the category of Share Issue/Capital Change announcements.
2013-07-11 Chinese
2013年半年度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast for the half-year period ending June 30, 2013, issued by the company's board. It provides estimated financial results (net profit and earnings per share) for the first half of 2013 compared to the same period in 2012. It explicitly states that the forecast is unaudited and that the final detailed financial data will be in the 2013 half-year report. The document is short (903 characters) and serves as an announcement of expected financial results rather than a full interim report containing actual financial statements or substantive analysis. Therefore, it is best classified as an Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results with key highlights only. H1 2013
2013-07-11 Chinese
资本公积金转增股本实施公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from 普洛药业股份有限公司 regarding the implementation of a capital reserve fund conversion to share capital, approved at the 2012 annual shareholders meeting. It details the share capital increase, dates for record and ex-rights, and the method of share distribution. The document is short (1488 characters) and focuses on the capital increase event rather than providing comprehensive financial statements or analysis. It is not a full financial report but an announcement of a capital change event. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2013-06-14 Chinese
2012年度股东大会的法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2012 Annual General Meeting (AGM) of 普洛药业股份有限公司. It details the legality and validity of the AGM's convening, attendance, and voting procedures. The document does not contain the actual annual report or financial statements but rather certifies the proper conduct of the AGM. The document length is 2935 characters, which is relatively short and consistent with a legal opinion letter rather than a full report. The content focuses on the AGM process and legal compliance, which aligns with the category of AGM Information (AGM-R).
2013-05-28 Chinese
提示性公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (897 characters) from a company disclosing audited financial data of its major shareholder after the company's 2012 annual report was published. It references the 2012 annual report but does not contain the full report itself or detailed financial statements. The document serves as a supplementary disclosure or update rather than the full annual report. It is not a certification letter, nor a voting result or management change announcement. Given its brevity and nature, it fits best as a Regulatory Filing (RNS) rather than the full Annual Report (10-K) or Report Publication Announcement (RPA).
2013-05-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.